Stoke Therapeutics, Inc.
STOK
$31.27
-$0.04-0.13%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 49.70% | 344.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 49.70% | 344.29% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | 49.70% | 344.29% | |||
| SG&A Expenses | 26.43% | -5.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.33% | -5.08% | |||
| Operating Income | -22.48% | 13.06% | |||
| Income Before Tax | -23.23% | 13.69% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.23% | 13.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.23% | 13.69% | |||
| EBIT | -22.48% | 13.06% | |||
| EBITDA | -22.64% | 13.20% | |||
| EPS Basic | -17.72% | 15.09% | |||
| Normalized Basic EPS | -17.70% | 15.08% | |||
| EPS Diluted | -17.72% | 15.51% | |||
| Normalized Diluted EPS | -17.70% | 15.08% | |||
| Average Basic Shares Outstanding | 4.68% | 1.65% | |||
| Average Diluted Shares Outstanding | 4.68% | 1.65% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||